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Purpose: To compare the cancer detection rate in patients with raised serum prostate-specific antigen (PSA) or abnormal digital rectal 
examination (DRE) results between the 10-core and the 16-core biopsy techniques in an Indian population. 
Methods: Between November 2010 and November 2012, 95 men aged >50 years who presented to the Urology Department with 
lower urinary tract symptoms, elevated serum PSA, and/or abnormal DRE findings underwent transrectal ultrasonography (TRUS)-
guided prostate biopsy. A total of 53 patients underwent 10-core biopsy and 42 patients underwent 16-core biopsy.
Results: Of the 53 men in the 10-core group, 8 had cancer, whereas in the 16-core biopsy group, 23 of 42 men had cancer. Detection 
of prostate cancer was significantly higher in patients who underwent 16-core biopsy than in those who underwent 10-core biopsy 
(P<0.001). Among the 95 men, 44 men had abnormal DRE findings (46.3%), of whom 23 showed cancer (52.27%). Of 51 men with 
normal DRE findings and elevated PSA, 8 men had malignancy with a cancer detection rate of 15.68%. Among 20 men with PSA between 
4.1 and 10 ng/mL, 2 (10%) had cancer. In 31 men with PSA between 10.1 and 20 ng/mL, 3 cancers (9.67%) were detected, and in 44 men 
with PSA >20 ng/mL, 26 cancers were detected (59.09%).
Conclusions: The cancer detection rate with 16-core TRUS-guided biopsy is significantly higher than that with 10-core biopsy (54.76% 
vs. 15.09%, P<0.001). In patients with both normal and abnormal DRE findings, 16-core biopsy has a better detection rate than the 
10-core biopsy protocol. With increasing PSA, there is a high rate of detection of prostate cancer in both 10-core and 16-core biopsy 
patients. 
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INTRODUCTION
Prostate cancer has been the most common non cutaneous 
malignancy in United States men since 1984 and now ac-
counts for one-quarter of all such cancers (American Cancer 
Society, 2008). Its incidence varies widely between countries 
and ethnic populations, with disease rates differing by more 
than 100-fold. The incidence is highest in African Americans 
(272 cases/100,000 men/yr) and lowest in Asian Chinese (1.9 
cases/1,00,000) [1]. In the Indian population, the incidence 
ranges from 5.39 to 6.58/100,000 [2]. Use of serum prostate-
specific antigen (PSA), digital rectal examination (DRE), and 
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transrectal ultrasonography (TRUS)-guided biopsy of the 
prostate have led to increased detection of early-stage prostate 
cancer and a decrease in mortality. The method introduced by 
Hodge et al. [3] involving 6 systematic sextant TRUS-guided 
biopsies has been the gold standard protocol for this purpose. 
However, it is associated with a relatively high false-negative 
rate of 15% to 31% [4,5]. Because of concern about the pos-
sibility of missing clinically significant tumors, several inves-
tigators have considered different regimens involving more 
extensive sampling of the gland, particularly the far lateral 
aspects of the peripheral zone of the prostate [6,7]. Although 
it is evident that increased sampling of the peripheral zone 
increases the cancer yield, there is no universally accepted 
technique for prostate gland biopsy. Hence, we planned to 
study 16-core biopsy in a subset of our study population and 
compare it with 10-core biopsy.
MATERIALS AND METHODS
This prospective observational study was carried out in our 
department between November 2010 and November 2012. 
All male patients above 50 years of age presenting to the urol-
ogy outpatient department with lower urinary tract symptoms 
were evaluated by DRE and serum PSA. Patients who had ab-
normal DRE findings or raised PSA were enrolled in the study 
(95 patients) and were further evaluated by TRUS-guided bi-
opsy for diagnosing prostate cancer. In patients with normal 
DRE findings and PSA elevation, repeat PSA testing was done. 
If both PSA levels were above 4 ng/mL, the patient was sub-
jected to TRUS-guided biopsy. In the initial consecutive 53 
patients, a 10-core biopsy was done, and in the remaining 42 
patients, a 16-core biopsy was performed. Patients unable or 
unwilling to give informed consent, patients with mental dis-
orders, and patients with urinary tract infection or a history of 
previous prostate surgery were excluded from the study. Prior 
approval was obtained from the Institutional Ethics Commit-
tee.
1. TRUS biopsy procedure
TRUS-guided prostate biopsy is done as an outpatient pro-
cedure. A proctoclysis enema was given on the day of biopsy. 
Patients taking anticoagulants and anti-platelets were advised 
to stop medication 5 days prior to biopsy. Written informed 
consent was obtained for inclusion in the study. Local anaes-
thesia was given by per rectal instillation of Lignocaine jelly 5 
to 10 minutes before the TRUS biopsy procedure. TRUS im-
aging of the prostate was done with the patient in the left lat-
eral decubitus position with a Pro Focus UltraView-2202 (BK 
Medical ApS, Herlev, Denmark) using a biplane transrectal 
probe (6–12 MHz). Prostate imaging was done simultaneously 
in the longitudinal and transverse planes, prostate volume was 
calculated, and any abnormalities in the prostate were noted. 
The Pro-Mag Ultra automatic biopsy instrument (Angiotech 
Pharmaceuticals Inc., North Bend, WA, USA) with an 18-G, 
20-cm needle was used for prostate biopsy. 
 The sites of the 10 cores (Fig. 1A) were as follows: 
right periphery, 3 (1 base, 1 mid, 1 apex); right parame-
dian, 2 (1 mid, 1 apex); left periphery, 3 (1 base, 1 mid, 1 
apex); left paramedian, 2 (1 mid, 1 apex).
 The sites of the 16 cores (Fig. 1B) were as follows: 
right periphery, 4 (1 base, 2 mid, 1 apex); right parame-
dian, 4 (1 base, 2 mid, 1 apex); left periphery, 4 (1 base, 2 
mid, 1 apex); left paramedian, 4 (1 base, 2 mid, 1 apex).
 On TRUS imaging of the prostate, any altered echotexture 
abnormalities of the prostate were noted and a systematic 
10- or 16-core biopsy was done including the abnormal areas 
in the biopsy region. Tissue bits collected in 10- and 16-core 
biopsy procedures were placed in tissue paper bits and kept 
in 4% formalin. Each core was sent in a separate bottle to the 
pathology department for histopathological examination. Pa-
tients were advised to take oral antibiotics (levofloxacin 250 
mg+ornidazole 500 mg twice daily) and analgesics (combina-
tion of tramadol 50 mg+paracetamol 500 mg twice daily) for 3 
days starting from the day of biopsy. The results of the biopsy 
and the complications of the procedure were studied in the 
10- and 16-core groups.
2. Statistical analysis
The statistical analysis was carried out by using SPSS ver. 16.0 
Fig. 1. Prostate biopsy sites. (A) 10 cores, (B) 16 cores. RP, right 
periphery; RPM, right paramedian; LP, left periphery; LPM, left 
paramedian.
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(SPSS Inc., Chicago, IL, USA). The data are summarized in 
tabular form. Continuous data are presented as means and 
standard deviations and between-group analysis was carried 
out by using Student t-test. Categorical data are presented as 
actual numbers and percentages. Categorical variables were 
analyzed with the chi-square test. For statistical significance, 
a probability (P) value of less than 0.05 was considered.
RESULTS
In this study, we analyzed the results of TRUS-guided prostate 
biopsy in men suspected of having prostate cancer on the 
basis of the results of the DRE or PSA measurement. Among 
95 patients subjected to TRUS-guided prostate biopsy, pros-
tatic adenocarcinoma was detected in 31 (32.6%), high-grade 
prostatic intraepithelial neoplasia in 12 (12.62%), fibroaden-
oleiomyomatous hyperplasia in 32 (32.58%), fibroadenoleio-
myomatous hyperplasia with chronic prostatitis in 5 (5.20%), 
and chronic prostatitis in 15 patients (15.78%). The age range 
of all the patients was between 50 and 85 years. In patients 
between the ages of 51 and 60 years, 8 of 30 had cancer; in 
patients between 61 and 70 years, 11 of 38 had cancer; in 
patients between 71 and 80 years, 10 of 22 had cancer; and in 
patients older than 80 years, 2 of 5 had cancer, respectively. 
The cancer detection rate increased with increasing age. Of 
53 men in the 10-core group, 8 had cancer on TRUS biopsy, 
whereas in the 16-core biopsy group, 23 of 42 had cancer (Ta-
ble 1). Detection of prostate cancer was significantly higher 
in patients who underwent 16-core biopsy than in those who 
underwent 10-core biopsy (P < 0.001) (Table 1). Among 95 
men, 44 men had abnormal DRE findings (46.3%), of whom 
23 had evidence of malignancy with a cancer detection rate 
of 52.27%. All these 44 patients with abnormal DRE findings 
had elevated serum PSA levels. Of 51 men with normal DRE 
findings and elevated PSA, 8 had evidence of malignancy on 
biopsy with a cancer detection rate of 15.68% (Table 2).
 Among 22 patients with abnormal DRE findings in the 10-
core group, 6 patients were found to have cancer, whereas in 
the 16-core group, 17 of 22 patients with abnormal DRE find-
ings had cancer (P = 0.002) (Table 2). In patients with normal 
DRE findings, 2 of 31 patients in the 10-core group had cancer 
positivity, whereas 6 of 20 patients in the 16-core group had 
cancer positivity (P = 0.04) (Table 2).
 All 95 patients had a serum PSA level of more than 4 ng/
mL. Among the 20 men with a PSA value between 4.1 and 10 
ng/mL, 2 (10%) had cancer. In 31 men with PSA between 10.1 
and 20 ng/mL, 3 cancers (9.67%) were detected, and in 44 
men with PSA >20 ng/mL, 26 cancers were detected (59.09%). 
The cancer detection rate with increasing PSA was statistically 
significant (P<0.0013) in the group of patients whose PSA was 
more than 20 ng/mL
 In the 10-core group, 14 patients had a PSA value in the 
range of 4 to 10 ng/mL, 21 patients had a value in the range of 
10.1 to 20 ng/mL, and 18 patients had a value of more than 20 
ng/mL. Of them, 1 patient in the lowest range of PSA values 
had cancer, 2 patients in the middle PSA range had cancer, 
and 5 patients in the upper PSA range had cancer (Table 3). In 
the 16-core group, 1 of 6 patients with a PSA value in the range 
of 4 to 10 ng/mL, 2 of 9 patients with a PSA value in the range of 
10.1 to 20 ng/mL, and 20 of 27 patients with a PSA value in the 
range of more than 20 ng/mL had cancer (Table 3). 
 We did not encounter any major complications in any of 
Table 2. Cancer detection rate in patients with abnormal DRE findings versus normal DRE findings in the 10-core and 16-core groups
Variable
Abnormal  DRE Normal DRE
10 Cores 16 Cores P-value 10 Cores 16 Cores P-value
No. of patients 22 22 31 20
Positive patients for cancer 6 17 0.002 2 6 0.040
DRE, abnormal digital rectal examination.
Table 1. Overall cancer detection rate in the 10-core and 16-
core groups
Group Positive patients for cancer, n (%) P-value
10 Cores (n=53) 8 (15.68)
16 Cores (n=42) 23 (54.76) 0.001
Table 3. Cancer detection in comparison with PSA in the 10-
core and 16-core groups
Group 
PSA  
(ng/mL)
No. of  
patients
No. of  
cancers 
detected
Cancer  
detection 
rate (%)
P-value
10 Cores 0.09
4–10 14 1 7.14
10.1–20 21 1 4.76
>20 18 6 33.34
16 Cores 0.02
4–10 6 1 16.60
10.1–20 9 2 22.23
>20 27 20 74.07
PSA, prostate-specific antigen.
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the 95 patients. Minor complications such as mild hematuria, 
perineal pain, and transient rectal bleeding were comparable 
in both 10-core and 16-core groups of patients and were man-
aged accordingly.
DISCUSSION
Prostate cancer is rarely diagnosed in men younger than 50, 
accounting for only 2% of all cases [8]. The median age at di-
agnosis is 68 years [9]. In our study, among men between 51 
and 60 years of age, 8 cancers (26%) were detected on TRUS 
biopsy; among men aged 61 to 70 years, 11 cancers (28%) were 
detected; among men aged 71 to 80 years, 10 cancers (45%) 
were detected; and among men aged >80 years, 2 cancers 
(40%) were detected. The cancer detection rate increased with 
increasing age. The median age in our study was 69 years.
 In our study, in the initial 53 consecutive patients, 10-core 
biopsy was done. In this group, the cancer detection rate was 
only 15.09%. Owing to the low detection rate, we felt that the 
gland was not adequately sampled by the 10-core method 
and hence a widespread sampling of the peripheral zone of 
the prostate was adopted by doing a 16-core biopsy in the lat-
er 42 patients. In the 16-core technique, the peripheral zone 
was divided into four quadrants, and 4 biopsies were taken 
from each quadrant (Fig. 1).
 Matlaga et al. [10] reviewed the English literature for the 
current indications and methods of prostate biopsy. In that 
review, the most widely accepted indication for prostate bi-
opsy was a PSA value of greater than 4.0 ng/mL apart from 
an abnormal DRE finding. The current literature describes a 
trend toward increasing the number of cores obtained and 
the sites biopsied beyond those of the standard sextant tech-
nique. The additional cores in many series are obtained from 
more lateral regions of the gland, and although several crite-
ria are used as indications for initial prostate biopsy, all are 
based on PSA level and/or abnormal DRE findings. There is 
no universally accepted technique for prostate gland biopsy.
 An abnormal DRE finding is an absolute indication for 
prostate biopsy. But DRE has only fair reproducibility in the 
hands of experienced examiners and misses a substantial 
proportion of early cancers [11]. Overall, the sensitivity of 
DRE in diagnosing prostate cancer in various studies ranges 
from 18% 68%. In our study, of a total of 95 patients, 44 had an 
abnormal DRE finding in the form of a nodule or induration 
of the prostate. All these 44 patients also had elevated serum 
PSA. Cancer was diagnosed in 23 patients (52.27%) with ab-
normal DRE findings (Table 2).
 In patients with normal DRE findings, cancer was detected 
in 8 of 53 patients (15.68%), which emphasizes the fact that 
biopsy is necessary in patients with raised PSA with negative 
DRE findings. The cancer detection rate in the 16-core group 
was higher than in the 10-core group (6 out of 20 versus 2 out 
of 31), even in the patients with normal findings DRE (Table 
2). In 1992, the cancer detection rate for patients with PSA lev-
els of 4 to 10 ng/mL and a normal DRE finding was reported to 
be 5.5% [12]. Recent data suggest that the current cancer de-
tection rate is 20% to 30% for patients with a PSA of 4–10 ng/
mL [13,14]. This could be due to changing patterns of biopsy 
techniques, including extended biopsy protocols. Catalona 
et al. [15] found that increasing the PSA cutoff to 4.5 ng/mL 
among men aged 60 to 69 years would result in 15% fewer bi-
opsy sessions but would miss 8% of organ-confined cancers 
[15].
 In our study, among the patients with normal DRE find-
ings, 1 of 14 patients (7.1%) with PSA of 4 to 10 ng/mL and 2 of 
19 patients (10.52%) with PSA of 10.1 to 20 ng/mL had cancer. 
The low cancer detection rate in lower PSA ranges could be 
explained by the non malignant pathologies contributing to 
elevated PSA in our study population (Table 3).
 Serum PSA levels greater than 20 ng/mL have been associ-
ated with cancer detection rates greater than 70%, and it is 
uncommon for BPH or chronic prostatitis to increase the PSA 
to these high levels without concurrent cancer in the gland 
[16-18]. In our study, in patients with PSA levels greater than 
20.1 ng/mL, the cancer detection rate was 59.09% (Table 3).
 Multiple in vivo studies have revealed that increasing the 
number of prostate biopsies enhances prostate cancer detec-
tion [19-21]. Eskew et al. [20] performed the first prospective 
study comparing the sextant biopsy method with a 13-core 
biopsy method. In that study, in addition to the traditional 
sextant regions (6 cores), 4 cores (2 from each side) from the 
far lateral regions (“anterior horn” or “lateral” biopsies) and 3 
midline biopsies were taken. Those authors found a statisti-
cally significant advantage (35% greater detection) with the 
additional cores of the 5-region biopsy. Babaian et al. [22] in-
vestigated an 11-core biopsy method in 362 patients, which in-
cluded sextant biopsies as well as 1 biopsy from the far lateral 
region (anterior horn), midline, and bilateral transition zones 
(adjacent and anterior to the urethra). That study revealed 
an overall increase of 33% in the prostate cancer detection 
rate, which was statistically significant. Presti et al. [23] evalu-
ated systematic prostate biopsy in 483 patients. This biopsy 
scheme obtains 10 samples from the prostate, 6 samples from 
the traditional sextant regions, and 2 cores from each of the 
lateral regions (peripheral zones). This method is similar to 
the 5-region technique, with the exception that the midline 
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biopsies are eliminated. They found that systematic cores 
taken from the traditional sextant region and lateral base and 
lateral mid portion of the gland could detect 96% of the can-
cers diagnosed. Contrary to the above studies, Naughton et al. 
[24] in their randomized study of 244 patients found that the 
cancer detection rate in the 6- and 12-core groups was almost 
identical (26% and 27%, P = 0.9) [24].
 In our study, the overall cancer detection rate in both the 
10- and 16-core groups was 32%, i.e., 31 of 95. In the 10-core 
group, the detection rate was 15.09% (8 of 53), whereas in the 
16-core group it was 54.76% (23 of 42) (Table 1). The detec-
tion rate was significantly higher in the 16-core group than in 
the 10-core group (P = 0.001). On evaluation, we found that 
there was no statistical significance in the detection of cancer 
among patients who underwent 10-core biopsy with rising 
PSA levels (P = 0.09). However, in the 16-core biopsy group, 
we found a statistically significant difference in the detec-
tion of cancer with rising PSA levels (P = 0.02) (Table 3). On 
further evaluation in patients having a PSA level > 20 ng/mL, 
we found a significant increase in detection of cancer among 
patients who underwent 16-core biopsy compared with 10-
core biopsy (6 patients out of 18 versus 20 patients out of 27; 
P = 0.005) (Fig. 2). 
 The limitation of our study was that it was not a random-
ized study. Also, we did not include the follow-up data of pa-
tients who had a negative prostate biopsy result, which might 
have some bearing on the statistical analysis.
 In conclusion, the results of our study support the available 
literature that the DRE and serum PSA are efficient tools in 
directing treating physicians whether to proceed for prostatic 
biopsy. The triad of PSA, DRE, and TRUS-guided prostatic bi-
opsies increases the probability of prostate cancer detection. 
Also, the cancer detection rate is high when abnormalities are 
found in both the DRE and PSA (52.27%) compared with el-
evated PSA alone (15.68%). Our study is unique in that it com-
pared the results of 10-core with those of 16-core prostate bi-
opsy for the first time in an Indian population. The detection 
rate with 16-core TRUS-guided biopsy was significantly high-
er than with 10-core biopsy (54.76% vs. 15.09%, P < 0.001). In 
patients with both normal and abnormal DRE findings, 16-
core biopsy has a better detection rate compared with the 10-
core biopsy protocol. With increasing PSA, there is a high rate 
of detection of prostate cancer in patients undergoing both 
10-core and 16-core prostate biopsy, although the rate is sig-
nificantly higher in the 16-core prostate biopsy group. 
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